CRLX101
Sponsors
NewLink Genetics Corporation, Massachusetts General Hospital, UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Conditions
Fallopian Tube CancerMetastatic Castration Resistant Prostate CancerMetastatic Renal Cell CarcinomaNon-Small Cell Lung CancerOvarian CancerPrimary Peritoneal CancerProstate NeoplasmsRectal Cancer
Phase 1
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
TerminatedNCT02010567
Start: 2013-12-31End: 2019-06-25Updated: 2020-11-03
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
TerminatedNCT02389985
Start: 2015-07-31End: 2018-10-18Updated: 2020-05-28
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
TerminatedNCT02648711
Start: 2015-10-31End: 2018-05-07Updated: 2020-05-28
Phase 2
A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer
CompletedNCT01380769
Start: 2011-06-30End: 2014-10-31Updated: 2020-05-28
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
CompletedNCT01652079
Start: 2012-04-30End: 2018-03-31Updated: 2018-07-02
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
CompletedNCT02187302
Start: 2014-07-31End: 2017-01-31Updated: 2020-05-28
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
TerminatedNCT03531827
Start: 2019-03-26End: 2021-06-01Updated: 2022-07-12